ENRIQUE MARÍA
OCIO SAN MIGUEL
Investigador en el periodo 2013-2018
Harvard Medical School
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Harvard Medical School (11)
2024
-
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
Haematologica, Vol. 109, Núm. 3, pp. 867-876
2022
-
Melflufen for the treatment of multiple myeloma
Expert Review of Clinical Pharmacology
2020
-
Melflufen: A peptide–drug conjugate for the treatment of multiple myeloma
Journal of Clinical Medicine, Vol. 9, Núm. 10, pp. 1-16
2019
-
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
The Lancet, Vol. 394, Núm. 10214, pp. 2096-2107
-
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study
British Journal of Haematology
2014
-
Future agents and treatment directions in multiple myeloma
Expert Review of Hematology, Vol. 7, Núm. 1, pp. 127-141
-
New drugs and novel mechanisms of action in multiple myeloma in 2013: A report from the International Myeloma Working Group (IMWG)
Leukemia, Vol. 28, Núm. 3, pp. 525-542
-
Preclinical activity of the oral proteasome inhibitor mln9708 in myeloma bone disease
Clinical Cancer Research, Vol. 20, Núm. 6, pp. 1542-1554
2013
-
Response assessment in Waldenström macroglobulinaemia: Update from the VIth International Workshop
British Journal of Haematology, Vol. 160, Núm. 2, pp. 171-176
2008
-
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo
Cancer Research, Vol. 68, Núm. 13, pp. 5216-5225
2006
-
Update on recommendations for assessing response from the Third International Workshop on Waldenström's macroglobulinemia
Clinical Lymphoma and Myeloma, Vol. 6, Núm. 5, pp. 380-383